ORIONS Money Stocks

[LaJollaCA]

News on CVM:

http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cvm

Co announces the Institutional Review Board of the U.S. Navy's Naval Medical Center San Diego, has approved the start of a Phase I dose escalation study of the Company's investigational immunotherapy Multikine in HIV/HPV co-infected men and women with peri-anal warts. This approval marks the third indication for which Multikine is being investigated in clinical trials. Multikine is currently being investigated in the largest Phase III trial in the world for the treatment of head and neck cancer. It has previously been evaluated as a potential treatment for cervical dysplasia in HIV/HPV co-infected women and a Phase II study to further investigate this indication is currently in the planning stages.

The Phase I dose escalation study is being funded and conducted through a Cooperative Research and Development Agreement between the U.S. Navy and CEL-SCI.
CEL-SCI will contribute the investigational immunotherapy drug Multikine, will retain all rights to any currently owned technology and will have the right to exclusively license any new technology developed from the collaboration.
By entering into this CRADA, NMCSD does not directly or indirectly endorse any product or service provided, or to be provided, by CEL-SCI, its successors, assignees, or licensees.